

CATALYST

Appendix 6 – CATALYST schedule of events for intervention arms**Arm 2: Gemtuzumab Ozogamicin (Mylotarg):**

| | Baseline | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 (+24 hrs) | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 (+24 hrs) | Day 11 | Day 12 | Day 13 | Day 14 | Day 15 – Day 27 | Day 28 ^o |
|---|----------|-------|-------|-------|-------|-----------------|-------|-------|-------|-------|------------------|--------|--------|--------|--------|-----------------|---------------------|
| IMP pre-medications # | | x | | | | x | | | | | x | | | | | | |
| IMP Administration – Mylotarg | | x | | | | x | | | | | x | | | | | | |
| Liver function test π | | x | | | | x | | | | | x | | | | | | |
| Vital signs (heart rate, blood pressure, temperature) ~ | | x | | | | x | | | | | x | | | | | | |

⊠ Information on Serious Adverse Events (SAEs) will be collected until 28 days after the last IMP administration, which may be after this time point.

Dexamethasone (9.9mg), antihistamine (chlorpheniramine 4-8mg PO or 10mg IV), paracetamol (1g PO or IV) to be given one hour prior to administration.

π Liver function test must be obtained (within the last 24hrs) and REVIEWED prior to IMP administration.

~ Vital signs must be monitored during the infusion and the patient observed for 4 hours after the infusion has ended.

Arm 3: Namilumab

| | Baseline | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 | Day 11 | Day 12 | Day 13 | Day 14 | Day 15 – Day 27 | Day 28 ^o |
|---|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|-----------------|---------------------|
| IMP administration – Namilumab | | x | | | | | | | | | | | | | | | |
| Vital signs (heart rate, blood pressure, temperature) ~ | | x | | | | | | | | | | | | | | | |

⊠ Information on Serious Adverse Events (SAEs) will be collected until 28 days after the last IMP administration, which may be after this time point.

~ Vital signs must be monitored during the infusion and the patient observed for 1 hour after the infusion has ended

CATALYST

Arm 4: Infliximab (Remsima)

| | Baseline | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 | Day 11 | Day 12 | Day 13 | Day 14 | Day 15 – Day 27 | Day 28 ^o |
|---|----------|-------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|-----------------|---------------------|
| IMP pre-medications # | | X | | | | | | | | | | | | | | | |
| IMP Administration - Infliximab | | X | | | | | | | | | | | | | | | |
| Vital signs (heart rate, blood pressure, temperature) ~ | | X | | | | | | | | | | | | | | | |

△ Information on Serious Adverse Events (SAEs) will be collected until 28 days after the last IMP administration, which may be after this time point.

PRN only - antihistamine (chlorpheniramine 4-8mg PO or 10mg IV), paracetamol (1g PO or IV) to be given one hour prior to administration at local centre discretion.

~ Vital signs must be monitored during the infusion and the patient observed for 2 hours after the infusion has ended.